Article
The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial.
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association - 1 Jan 2000
AlEid Ahmad, Al Balkhi Areej, Qutub Adel, Abbarh Shahem, AlLehibi Abed, Almtawa Abdullah, Al Otaibi Nawwaf, AlGhamdi Ahmed, AlGhamdi Adel, Alamr Abdulrahman, Ahmad Shameem, Al Sayari Khalid, Al Ibrahim Bashaar, AlKhathlan Abdullah
Abstract excerpt
Background: Cost, adverse events, and long treatment duration can be significant obstacles in treating hepatitis C virus (HCV)-infected individuals. Shortening the treatment regimen can minimize these barriers, thereby enhancing adherence and increasing medication availability to more patients. Methods: This is a single-centre, single-arm, open-label, phase 3 clinical trial on treatment naïve, non-cirrhotic, HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.